Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for MaxCyte, Inc. (MXCT:NASDAQ), powered by AI.
MaxCyte, Inc. is currently trading at $1.12. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for MaxCyte, Inc. on Alpha Lenz.
MaxCyte, Inc.'s P/E ratio is -2.7.
“MaxCyte, Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -23.6%.”
Ask for details →MaxCyte Inc. is a biotechnology company that specializes in developing advanced cell engineering technology used across the biomedical industry. At the core of the company's operations is its proprietary electroporation platform, which enables precise, efficient, and scalable modifications of cells. This technology is pivotal for research and development in gene editing, cell therapy, and immune-oncology, fields that are rapidly evolving and gaining significance in the fight against various diseases, including cancer. MaxCyte Inc. provides tools and systems to pharmaceutical companies and research institutions, facilitating the development of novel therapeutics. Founded with a strong focus on innovation, the company plays a crucial role in advancing personalized medicine by supporting breakthroughs in genetic engineering. Its strategic collaborations and partnerships highlight its integral role in the biotechnology market, delivering cutting-edge solutions that address unmet medical needs and contributing to the progress of treatments affecting patients globally.
“MaxCyte, Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -23.6%.”
Ask for details →MaxCyte, Inc. (ticker: MXCT) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 114 employees. Market cap is $119M.
The current price is $1.12 with a P/E ratio of -2.67x and P/B of 0.7x.
ROE is -23.63% and operating margin is -137.12%. Annual revenue is $33M.